Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Non-randomised Study of Modrenal (trilostane) in advanced estrogen receptor-positive breast cancer
2004-004533-34Phase 4Completed
- Sponsor
- Bioenvision
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of prednisolone in breast cancer, sponsored by Bioenvision. Primary endpoint: Clinical Benefit Rate at 3 and 6 months. Started Sep 2005; status: completed.
02
Drugs
prednisolone
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-004533-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004533-34.